PharmaJet’s Needle-free Injection System Selected to Administer DNA Immunotherapy for Advanced Melanoma in Late-stage Clinical Development following Positive Phase 2 Data
- PharmaJet’s intramuscular (IM) Needle-free Injection System – Stratis® – was used to deliver Scancell’s iSCIB1+ DNA immunotherapy in combination with immune checkpoint inhibitors in the SCOPE Phase 2 trial.
- The Scancell immunotherapy delivered using PharmaJet’s Stratis demonstrated a Progression-Free Survival rate of 74% at 16 months.1
GOLDEN, Colo. — January 9, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner Scancell has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma. In this study, Scancell’s iSCIB1+ immunotherapy was delivered intramuscularly using Stratis, PharmaJet’s Needle-free Injection System. Data was presented at the ESMO Immuno-Oncology Congress 2025 on December 11, 2025.
